- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04100525
Intervention for Employed Women With Multiple Sclerosis
February 16, 2021 updated by: Holy Name Medical Center, Inc.
Neuropsychological Feedback Style and Case Management to Improve Intervention Outcome for Employed Women With Multiple Sclerosis: a Randomized Clinical Trial
Unemployment is particularly common among women with multiple sclerosis (MS).
This study uses a vocational rehabilitation program involving neuropsychological testing as an intervention.
The use of in-person feedback and case management following neuropsychological testing is compared to phone feedback only.
Adherence to treatment and employment outcomes will be evaluated over three years.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Employed women at a tertiary-care MS center were screened for common issues impacting work productivity (fatigue, cognitive dysfunction, and depression).
Women who met screening criteria were randomized to one of two treatment groups: either neuropsychological testing and phone feedback to review findings and tailored recommendations (standard-care treatment); or neuropsychological testing, in-person feedback, and two calls from a care-coordinator (experimental treatment).
Adherence to recommendations and employment status at one year are evaluated.
Follow-up periods also occur at year two and year three.
Study Type
Interventional
Enrollment (Actual)
89
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 64 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Female sex
- Age between 18 and 64
- Employed at least 20 hours per week
- Confirmed diagnosis of MS
Exclusion Criteria:
- Experiencing an MS exacerbation
- Endorsing suicidal ideation or intent
- Pregnant
- Severe psychiatric disorder
- History of traumatic brain injury
- Dementia
- Major neurological illness other than MS
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: Standard Care
Participant received neuropsychological testing, report detailing cognitive strengths and weaknesses, tailored recommendations to address areas of weakness (including psychological and/or physical symptoms impacting work productivity).
Participant received a copy of this report in the mail and a call from the psychologist to go over test findings and recommendations.
|
Neuropsychological testing for women experiencing significant fatigue, mood, or cognitive symptoms.
Feedback type and case management services varied depending on randomized group.
|
|
EXPERIMENTAL: Experimental Treatment
Participant received neuropsychological testing, report detailing cognitive strengths and weaknesses, tailored recommendations to address areas of weakness (including psychological and/or physical symptoms impacting work productivity).
Participant then receives in-person feedback (and a copy of the report at this visit) and two calls from a care-coordinator research nurse at approximately 1 and 6 months post feedback, who asks participant whether they completed recommendations and assist participant in completing recommendations where possible (i.e., help find a provider, explanation of importance of completing recommendations, etc).
|
Neuropsychological testing for women experiencing significant fatigue, mood, or cognitive symptoms.
Feedback type and case management services varied depending on randomized group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Employment
Time Frame: Approximately 12 months
|
Has there been a decrease in employment status (Yes/No)
|
Approximately 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adherence to Recommendations
Time Frame: Approximately 12 months
|
Percentage of recommendations completed at one year
|
Approximately 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Frederick W Foley, Ph.D., Holy Name Medical Center, Ferkauf Graduate School of Psychology
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
April 1, 2016
Primary Completion (ACTUAL)
February 1, 2020
Study Completion (ANTICIPATED)
January 1, 2022
Study Registration Dates
First Submitted
September 20, 2019
First Submitted That Met QC Criteria
September 20, 2019
First Posted (ACTUAL)
September 24, 2019
Study Record Updates
Last Update Posted (ACTUAL)
February 18, 2021
Last Update Submitted That Met QC Criteria
February 16, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Employment Study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Neuropsychological testing intervention plus follow up
-
Institute of Psychiatry and Neurology, WarsawUnknown
-
Azienda Unita Sanitaria Locale di PiacenzaRecruitingHeart Failure With Reduced Ejection Fraction (HFrEF)Italy
-
Queen's University, BelfastBelfast Health and Social Care Trust; Southern Health and Social Care TrustWithdrawnCataract | Age-related Cataract
-
Assistance Publique - Hôpitaux de ParisRecruitingTourette SyndromeFrance
-
University of California, San FranciscoNational Institute of Mental Health (NIMH)Completed
-
St. Luke's Health System, Boise, IdahoPatient-Centered Outcomes Research Institute; University of Pennsylvania; Columbia... and other collaboratorsActive, not recruitingAdolescent | Depressive Disorder | Depression | Suicidal Ideation | Suicide, Attempted | Suicide | Mental Health | Loneliness | Social Support | Mental Disorder | Outpatients | Ambulatory Care | Continuity of Patient Care | Adult | Secondary Prevention | Emergency Service, Hospital | Mental Health Services | Patient Care Planning and other conditionsUnited States
-
The First Affiliated Hospital of Guangzhou Medical...Recruiting
-
Hillel Yaffe Medical CenterUnknownLateral Ventricles of Fetuses at Mid TrimesterIsrael
-
Seva Canada SocietyPragyaan Sustainable Health Outcomes Foundation; Sadgura Netra ChikitsalayaNot yet recruitingCataract (Post-operative Cataract Surgery Follow-up)
-
University of MonastirCompletedMinor Head InjuryTunisia